Clinical Trial Update: SGLT2 Inhibitors and Renal Anemia in Japan: RWD

View source ↗

Summary

Boehringer Ingelheim-sponsored real-world data study in Japan evaluating SGLT2 inhibitors for renal anemia in chronic kidney disease; the trial status is ACTIVE…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• SGLT2 inhibitors (class)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Chronic Kidney Disease | Status: ACTIVE_NOT_RECRUITING